<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00302328</url>
  </required_header>
  <id_info>
    <org_study_id>COMAH</org_study_id>
    <nct_id>NCT00302328</nct_id>
  </id_info>
  <brief_title>Trial of Prognostic Factors and Surgical Methods for the Treatment of Idiopathic Macular Holes</brief_title>
  <official_title>A Randomised Clinical Trial of Prognostic Factors and Surgical Methods for the Treatment of Idiopathic Macular Holes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Eye Health Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Danish Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Glostrup University Hospital, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project is a randomized clinical trial with a follow up time of 12 months comparing the
      effects of surgical treatment of idiopathic macular holes. Patients are randomized to
      vitrectomy alone, vitrectomy plus indocyanine green (ICG) assisted inner limiting membrane (
      ILM) peeling or vitrectomy plus trypan blue (tb) assisted ILM peeling. At baseline patients
      are characterized using early treatment diabetic retinopathy study (ETDRS) visual charts,
      tests of aniseikonia, optical coherence tomography 3 (OCT3), visual field and fundus
      photography. Per- and postoperative complications are registered.

      Data analyses will help clarify the effect of ILM peeling on hole closure and visual acuity.
      Comparing results after ICG- and tb assisted ILM peeling will help clarify the topic of a
      toxic effect on retinal cells after staining and peeling of the ILM. Changes in intraretinal
      morphology before and after dye-assisted ILM peeling will be studied using OCT3 imaging and
      the patients' subjective opinion on the surgical results will be analyzed using quality of
      life questionnaires and metamorphopsia tests.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity (ETDRS Letters)</measure>
    <time_frame>Visual acuity at 12 months</time_frame>
    <description>Visual acuity measured as the number of ETDRS letters at last follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anatomic Success</measure>
    <time_frame>macular hole closure at 12 months</time_frame>
    <description>closure of the macular hole evaluated on optical coherence tomography 3 (OCT3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Field Defects</measure>
    <time_frame>6 months</time_frame>
    <description>visual field defects measured on humphrey perimetry</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Idiopathic Macular Hole</condition>
  <arm_group>
    <arm_group_label>macular hole operation no peeling</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Macular hole operation ICG peeling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Macular hole operation TB peeling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>macular hole operation</intervention_name>
    <description>macular hole surgery with either no peeling, indocyanine green (ICG) assisted peeling or trypan blue (tb) peeling</description>
    <arm_group_label>Macular hole operation ICG peeling</arm_group_label>
    <arm_group_label>Macular hole operation TB peeling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic macular hele stage 2 or 3.

          -  Duration of Symptoms ≤ 12 months.

          -  Visual acuity ≥ 34 ETDRS letters.

          -  Intraocular pressure ≤ 23 mmHg.

          -  Informed consent.

        Exclusion Criteria:

          -  Previous macular hole in project eye

          -  Macular pucker worse than a cellophane macular reflex.

          -  Previous surgery or disease in the eye affecting retinal function.

          -  Systemic disease affection vision including diabetes mellitus with level of
             retinopathy ≥ 14a.

          -  Amblyopia i project eye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morten la Cour, MD,DMSc,EBOD</last_name>
    <role>Study Director</role>
    <affiliation>Glostrup Hospital, Department of Ophthalmology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Larsen, MD, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Glostrup Hospital, Department of Ophthalmology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ophthalmology, Glostrup Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2006</study_first_submitted>
  <study_first_submitted_qc>March 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2006</study_first_posted>
  <results_first_submitted>October 4, 2012</results_first_submitted>
  <results_first_submitted_qc>March 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 16, 2014</results_first_posted>
  <last_update_submitted>March 13, 2014</last_update_submitted>
  <last_update_submitted_qc>March 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Glostrup University Hospital, Copenhagen</investigator_affiliation>
    <investigator_full_name>Ulrik Christensen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Perforations</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>3 years</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>no Peeling</title>
          <description>no peeling used</description>
        </group>
        <group group_id="P2">
          <title>ICG Peeling</title>
          <description>indocyanine (ICG) peeling</description>
        </group>
        <group group_id="P3">
          <title>tb Peeling</title>
          <description>trypan blue (tb) peeling</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="34">developed cancer during the study</participants>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>no Peeling</title>
          <description>no peeling used</description>
        </group>
        <group group_id="B2">
          <title>ICG Peeling</title>
          <description>indocyanine green (ICG) peeling</description>
        </group>
        <group group_id="B3">
          <title>tb Peeling</title>
          <description>trypan blue (tb) peeling</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="18"/>
            <count group_id="B4" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.6" spread="5"/>
                    <measurement group_id="B2" value="66.9" spread="5"/>
                    <measurement group_id="B3" value="66.6" spread="5"/>
                    <measurement group_id="B4" value="66.6" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity (ETDRS Letters)</title>
        <description>Visual acuity measured as the number of ETDRS letters at last follow-up</description>
        <time_frame>Visual acuity at 12 months</time_frame>
        <population>Decided from initial power calculation</population>
        <group_list>
          <group group_id="O1">
            <title>no Peeling</title>
            <description>Vitrectomy without peeling</description>
          </group>
          <group group_id="O2">
            <title>ICG Peeling</title>
            <description>vitrectomy with icg-assisted ilm peeling</description>
          </group>
          <group group_id="O3">
            <title>tb Peeling</title>
            <description>vitrectomy with trypan blue assisted ilm peeling</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity (ETDRS Letters)</title>
          <description>Visual acuity measured as the number of ETDRS letters at last follow-up</description>
          <population>Decided from initial power calculation</population>
          <units>Visual acuity in letters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.9" spread="8.2"/>
                    <measurement group_id="O2" value="72.4" spread="6.5"/>
                    <measurement group_id="O3" value="72.2" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anatomic Success</title>
        <description>closure of the macular hole evaluated on optical coherence tomography 3 (OCT3)</description>
        <time_frame>macular hole closure at 12 months</time_frame>
        <population>from initial power calculation of primary end point</population>
        <group_list>
          <group group_id="O1">
            <title>no Peeling</title>
            <description>vitrectomy without ilm peeling</description>
          </group>
          <group group_id="O2">
            <title>ICG Peeling</title>
            <description>vitrectomy with icg assited ilm peeling</description>
          </group>
          <group group_id="O3">
            <title>tb Peeling</title>
            <description>vitrectomy with trypan blue assited ilm peeling</description>
          </group>
        </group_list>
        <measure>
          <title>Anatomic Success</title>
          <description>closure of the macular hole evaluated on optical coherence tomography 3 (OCT3)</description>
          <population>from initial power calculation of primary end point</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" spread="31"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Field Defects</title>
        <description>visual field defects measured on humphrey perimetry</description>
        <time_frame>6 months</time_frame>
        <population>from predetermined power analysis</population>
        <group_list>
          <group group_id="O1">
            <title>no Peeling</title>
            <description>vitrectomy without ilm peeling</description>
          </group>
          <group group_id="O2">
            <title>ICG Peeling</title>
            <description>vitrectomy with icg assited ilm peeling</description>
          </group>
          <group group_id="O3">
            <title>tb Peeling</title>
            <description>vitrectomy with trypan blue assisted ilm peeling</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Field Defects</title>
          <description>visual field defects measured on humphrey perimetry</description>
          <population>from predetermined power analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit=".1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>no Peeling</title>
          <description>vitrectomy without ilm peeling</description>
        </group>
        <group group_id="E2">
          <title>ICG Peeling</title>
          <description>vitrectomy with icg assited ilm peeling</description>
        </group>
        <group group_id="E3">
          <title>tb Peeling</title>
          <description>vitrectomy with trypan blue assited ilm peeling</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>macular hole did not close</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>non-closure of macular hole after surgical procedure in 18 patients led to re-operation. Data included in main published papers.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ulrik Christensen</name_or_title>
      <organization>Glostrup Hospital</organization>
      <phone>+4538634825</phone>
      <email>bisan@regionh.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

